Floatz logo

s241656

Thyroid Carcinoma

Institut de Recherches Internationales ServierPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Thyroid Carcinoma cohort.

Asset / SponsorPhaseRating
Palbociclib
University Medical Center Groningen
Phase 4BB
LENVATINIB
University Medical Center Groningen
Phase 4BB
Olaparib
University Medical Center Groningen
Phase 4BB
gw786034
University Medical Center Groningen
Phase 4B
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 39 →

Same molecule, other indications

s241656 is also rated in:

histiocytic and dendritic cell neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
histiocytosisDormant
CCC
Indicative ·
48 / 100
View asset →
BRAF Gene MutationDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →